PMID- 36238567
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221209
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety evaluations of anlotinib in patients with advanced non-small 
      cell lung cancer treated with bevacizumab.
PG  - 973448
LID - 10.3389/fphar.2022.973448 [doi]
LID - 973448
AB  - Objective: The purpose of this study is to evaluate the efficacy and safety of 
      anlotinib in patients with advanced non-small cell lung cancer (NSCLC) who had 
      previously received bevacizumab. Methods: The participants were 
      histopathologically or cytologically diagnosed advanced NSCLC patients whose 
      disease progressed after at least one type of systemic therapy and who had 
      previously received bevacizumab treatment. The patients were on 3-week 
      administration cycles, including 2 weeks on-treatment (12 mg anlotinib oral 
      route, once a day) and 1 week off-treatment. The primary end point of the trial 
      was overall survival (OS). The secondary end points were progression-free 
      survival (PFS), objective response rate (ORR), disease control rate (DCR) and 
      safety. Results: As of the data collection deadline (31 March 2021), 30 patients 
      were enrolled in the study and received anlotinib treatment. All patients were 
      included in the data set except one, who withdrew their consent after the start 
      of treatment. The median follow-up period was 12.1 months (range, 
      3.6-25.0 months), and 29 patients were included in the evaluation of the 
      treatment. Of the 29 patients, no CR cases occurred. In total, three patients 
      (10.2%) showed a PR, 21 (72.4%) had SD, and five patients (17.2%) had PD. The 
      objective response rate (ORR) was 10.2% (3 of 29 patients), and the disease 
      control rate (DCR) was 82.7% (24 of 29 patients). The median progression-free 
      survival (PFS) was 5.6 months (95% CI, 5.0-6.1 months; Figure 2). The median 
      overall survival (OS) was 10.6 months (95% CI, 9.4-11.8 months; Figure 3). The 
      overall tolerance of the anlotinib treatment was high among the enrolled 
      patients. No treatment-related grade four or five toxicities were observed. Of 
      the 29 patients, one patient's anlotinib administration was reduced to 8 mg/day 
      due to hypertension and headache. Most adverse events (AEs) were grade one or 
      two; the most common AEs were fatigue (51.7%), hypertension (41.3%), hand-foot 
      syndrome (41.4%), anorexia (34.5%) and hypertriglyceridemia (34.5%). Conclusion: 
      Anlotinib demonstrated favourable activity and manageable toxicity in NSCLC 
      patients who were treated with bevacizumab previously.
CI  - Copyright (c) 2022 Jiang, Li, Kong, Sun and Qu.
FAU - Jiang, Fenge
AU  - Jiang F
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Li, Junxia
AU  - Li J
AD  - Department of Radiation Oncology, The Affiliated Yantai Yuhuangding Hospital of 
      Qingdao University, Yantai, Shandong, China.
FAU - Kong, Xiangshuo
AU  - Kong X
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Sun, Ping
AU  - Sun P
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
FAU - Qu, Huajun
AU  - Qu H
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China.
LA  - eng
PT  - Systematic Review
DEP - 20220927
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
EIN - Front Pharmacol. 2022 Nov 22;13:1092147. PMID: 36483732
PMC - PMC9552664
OTO - NOTNLM
OT  - anlotinib
OT  - bevacizumab
OT  - efficacy
OT  - non-small cell lung cancer (NSCLC)
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/15 06:01
PMCR- 2022/09/27
CRDT- 2022/10/14 03:08
PHST- 2022/06/20 00:00 [received]
PHST- 2022/09/09 00:00 [accepted]
PHST- 2022/10/14 03:08 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/15 06:01 [medline]
PHST- 2022/09/27 00:00 [pmc-release]
AID - 973448 [pii]
AID - 10.3389/fphar.2022.973448 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Sep 27;13:973448. doi: 10.3389/fphar.2022.973448. 
      eCollection 2022.